A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
← catalyst calendarNCT05885412 · readout ≤ 773 d
Sponsored by Rocket Pharmaceuticals Inc. (industry) · RCKT — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
9estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-29 | actual | When the study began enrolling |
| Primary completion | Sep 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Intervention
- Genetic: RP-A601
Primary outcome
what the primary-completion date above is the date OFEvaluation of safety associated with RP-A601
measured 12 months post-infusion
Publications
- PMID 37979797 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · RCKT's whole pipeline · Catalyst calendar · Every registered study · What changed